Recalcitrant Lichen Planopilaris and Frontal Fibrosing Alopecia Responding to Tildrakizumab

The paper reported a case of recalcitrant lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) that showed significant clinical improvement after four doses of tildrakizumab, an interleukin-23 monoclonal antibody. LPP and FFA are types of lymphocytic, cicatricial alopecias, with LPP presenting as multifocal patchy alopecia and FFA causing hairline recession. The treatment aimed to arrest the inflammatory process, which is often challenging and yields variable responses.